Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Libertas Bio Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity involves 1 distinct examiner and 1 distinct art unit. ROSENTHAL, ANDREW S is the busiest examiner for the portfolio, overseeing 1 pending action.
The concentration of the workload in 1 distinct art unit suggests a specialized focus within the Biotechnology & Pharmaceuticals sector. For practitioners, the prosecution is currently tied to the individual review of ROSENTHAL, ANDREW S. This centralization means that the outcome of the 1 pending office action will be determined by the specific interpretations of this examiner.
Monitoring the examiner's history and the specific requirements of the 1 distinct art unit will be essential for navigating the current prosecution landscape for the company. The resolution of this 1 action will provide significant insight into the company's standing within the patent office. Practitioners should prepare for a focused interaction with ROSENTHAL, ANDREW S to move the portfolio forward.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ROSENTHAL, ANDREW S | 70d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ROSENTHAL, ANDREW S | 70d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ROSENTHAL, ANDREW S | 1613 | §103§112 | Final Rejection | 70d overdue | Pending | May 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial